digital microscopy spot advanced software v5.3 (Diagnostic Instruments Inc)
90
Structured Review
Diagnostic Instruments Inc
digital microscopy spot advanced software v5.3
Digital Microscopy Spot Advanced Software V5.3, supplied by Diagnostic Instruments Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/digital+microscopy+spot+advanced+software/digital+microscopy+spot+advanced+software+v5+3/pmc08908463-62-15-24
Average 90 stars, based on 1 article reviews
Digital Microscopy Spot Advanced Software V5.3, supplied by Diagnostic Instruments Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/digital+microscopy+spot+advanced+software/digital+microscopy+spot+advanced+software+v5+3/pmc08908463-62-15-24
Average 90 stars, based on 1 article reviews
digital microscopy spot advanced software v5.3 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Microscopy:Article Title: Inhibition of ribonucleotide reductase reduces neointimal formation following balloon injury. Article Snippet: Percutaneous transluminal coronary angioplasty (PTCA) has greatly benefited patients with occluded coronary arteries, but its benefits have been undermined by a high incidence of restenosis.. The introduction of coronary stents has significantly improved the short and long term outcome but restenosis still occurs in approximately 15 to 30% of patients within 6 months.. Research efforts are now being directed toward combination stenting and drug delivery. Software:Article Title: Inhibition of ribonucleotide reductase reduces neointimal formation following balloon injury. Article Snippet: Percutaneous transluminal coronary angioplasty (PTCA) has greatly benefited patients with occluded coronary arteries, but its benefits have been undermined by a high incidence of restenosis.. The introduction of coronary stents has significantly improved the short and long term outcome but restenosis still occurs in approximately 15 to 30% of patients within 6 months.. Research efforts are now being directed toward combination stenting and drug delivery. |